IFRX - InflaRx N.V.

-

$undefined

N/A

(N/A)

InflaRx N.V. NasdaqGS:IFRX InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Location: Winzerlaer Str. 2, Jena, 07745, Germany | Website: https://www.inflarx.de | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

47.3M

Cash

65.86M

Avg Qtr Burn

-11.93M

Short % of Float

1.98%

Insider Ownership

6.44%

Institutional Own.

26.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

Vilobelimab (IFX-1) Details
Skin disease/disorder, Autoimmune disease, Pyoderma gangraenosum

Big Mover™

Susp. Mover™

Phase 3

Data readout

IFX-1 (vilobelimab) Details
Skin disease/disorder, Hidradenitis suppurativa

Phase 2b

Data readout

INF904 (C5aR Inhibitor) Details
Chronic Autoimmune and Inflammatory Diseases

Phase 2a

Data readout

Vilobelimab (IFX-1) Details
Cancer, Cutaneous squamous cell carcinoma

Failed

Discontinued

IFX-1 (vilobelimab) Details
Autoimmune disease, Antineutrophil cytoplasmic antibody-associated vasculitis

Failed

Discontinued